Explore 3 Stock Ideas & Industry Insights Download Free Report

News

AmpliTech Group (NASDAQ:AMPG) Reports Third-Quarter Revenue of USD 6.6 Million and Record Backlog Above USD 52 Million

Founder and Chief Executive Officer Fawad Maqbool said the quarter showed year-over-year revenue growth, expansion in the O-RAN 5G and Spectrum divisions and gross margin improvement from the second quarter. He also said the timing of large 5G deployments andManufacturingexecution had not matched the …

Nitish Kishor | 13 November 2026

American Shared Hospital Services (NYSE American:AMS) Reports 13.7% Nine-Month Revenue Growth

Management said its broader priority remains disciplined management of its assets, strengthening its financial foundation and pursuing strategic opportunities that can contribute to sustainableLong-term GrowthandShareholdervalue.

Nitish Kishor | 13 November 2026

Andersen Group (NYSE:ANDG) Reports Third-Quarter Revenue of USD 337.3 Million and Issues 2027 Outlook

Chairman and Chief Executive Officer Mark Vorsatz said third-quarter revenue grew about 18.7%, or about USD 53 million, and that year-to-date revenue was about USD 795 million, up about 19.1%. Chief Financial Officer Neal Livingstone said last-twelve-month revenue was USD 966 million, up 19.2%, …

Nitish Kishor | 13 November 2026

Arcos Dorados (NYSE:ARCO) Reports 11% Revenue Growth and Sets 2027 to 2030 Growth Objectives

Adjusted EBITDA totaled USD 125.9 million with a consolidated margin of 9.5%. Underlying adjusted EBITDA grew 9%, with food and paper costs improving for the third consecutive quarter. Brazil's adjusted EBITDA grew about 10% in U.S. dollars from the prior-year quarter.

Nitish Kishor | 13 November 2026

Armata Pharmaceuticals (NYSE American:ARMP) Reports Third-Quarter Grant Revenue of USD 3.17 Million as FDA Grants Breakthrough Designation

The quarter also included regulatory progress for its lead candidate, AP-SA02, which is being developed for the treatment of complicated S. aureus bacteremia. The filing states that the FDA granted Breakthrough Therapy designation to AP-SA02 on September 14, 2026, and that the company obtained …

Nitish Kishor | 13 November 2026

Artelo Biosciences (NASDAQ:ARTL) Reports Nine-Month Net Loss of USD 7.2 Million and Cancer Anorexia Trial Update

The company incurred a net loss of USD 7,153 thousand during the nine months ended September 30, 2026, and held cash and cash equivalents of USD 4,437 thousand at September 30, 2026. The filing includes aGoing Concernsection describing losses since inception.

Nitish Kishor | 13 November 2026

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reports Fiscal 2026 Revenue of USD 450.8 Million and Submits Supplemental Application for REDEMPLO in sHTG

Total revenue for fiscal 2026 was USD 450.8 million, against USD 829.4 million in fiscal 2025. Collaboration and license revenue was USD 444.2 million and product revenue, net, was USD 6.6 million. The filing attributes the decrease to lower revenue recognition under the Sarepta …

Nitish Kishor | 13 November 2026

Accelerant Holdings (NYSE:ARX) Reports Third-Quarter Revenue of USD 278.6 Million and Adjusted EBITDA Up 25%

The company operates the Accelerant Risk Exchange, a platform that houses its technology and data capabilities for specialty underwriters. The filing says Exchange Services captures theRevenueand expenses associated with that platform.

Nitish Kishor | 13 November 2026

Assembly Biosciences (NASDAQ:ASMB) Reports Third-Quarter Collaboration Revenue of USD 3.0 Million and USD 314.3 Million in Cash and Securities

Collaboration revenue from a related party was USD 3.0 million for the three months ended September 30, 2026, against USD 10.8 million a year earlier. For the nine months, it was USD 24.5 million, against USD 29.8 million. The filing states the company recognized …

Nitish Kishor | 13 November 2026

Ascendis Pharma (NASDAQ:ASND) Reports Product Revenue of EUR 366 Million and Raises Cash Flow Guidance

Global Yorvipath revenue in the third quarter was EUR 291 million, up 103% over last year and up EUR 39 million from the second quarter. Management described Yorvipath as the first and only approved treatment for hypoparathyroidism in adults, now available commercially or through …

Nitish Kishor | 13 November 2026
Support

Hi! How can we help you today?

Loading…